The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Targeting protein kinases in central nervous system disorders
Open accessAbstract
Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues associated specifically with CNS drug discovery. However, several candidate therapeutics that target CNS protein kinases are now in various stages of preclinical and clinical development. We review candidate compounds and discuss selected CNS protein kinases that are emerging as important therapeutic targets. In addition, we analyse trends in small-molecule properties that correlate with key challenges in CNS drug discovery, such as blood–brain barrier penetrance and cytochrome P450-mediated metabolism, and discuss the potential of future approaches that will integrate molecular-fragment expansion with pharmacoinformatics to address these challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Kyriakis, J. M., & Avruch, J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.807 · Cited by 3,382
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., et al. (1997) · Nature · doi:10.1038/40187 · Cited by 2,859
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
p38 MAP-Kinases pathway regulation, function and role in human diseases
Cuenda, A., & Rousseau, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.03.010 · Cited by 1,400
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
The MEK/ERK cascade: From signaling specificity to diverse functions
Shaul, Y. D., & Seger, R. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.005 · Cited by 940
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Levin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 813
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Clinical Pharmacokinetics of Imatinib
Peng, B., Lloyd, P., & Schran, H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544090-00001 · Cited by 665
Rho Kinase Inhibition Enhances Axonal Regeneration in the Injured CNS
Fournier, A. E., Takizawa, B. T., & Strittmatter, S. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01416.2003 · Cited by 644
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Kinetic and Catalytic Mechanisms of Protein Kinases
Adams, J. A. (2001) · Chemical Reviews · doi:10.1021/cr000230w · Cited by 627
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Rho kinase, a promising drug target for neurological disorders
Mueller, B. K., Mack, H., & Teusch, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1719 · Cited by 608
The casein kinase 1 family: participation in multiple cellular processes in eukaryotes
Knippschild, U., Gocht, A., Wolff, S., Huber, N., Löhler, J., & Stöter, M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2004.12.011 · Cited by 601
Zalckvar, E., Berissi, H., Mizrachy, L., Idelchuk, Y., Koren, I., Eisenstein, M., Sabanay, H., Pinkas‐Kramarski, R., & Kimchi, A. (2009) · The EMBO Reports · doi:10.1038/embor.2008.246 · Cited by 592
Meikle, L., Pollizzi, K., Egnor, A., Kramvis, I., Lane, H., Sahin, M., & Kwiatkowski, D. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0955-08.2008 · Cited by 501
Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes
Jope, R. S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00206-2 · Cited by 500
LRRK2 in Parkinson's disease: protein domains and functional insights
Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P., & Gallo, K. A. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.03.006 · Cited by 489
MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia
Alessandrini, A., Namura, S., Moskowitz, M. A., & Bonventre, J. V. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12866 · Cited by 464
Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 455
Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140665 · Cited by 445
The Death-Associated Protein Kinases: Structure, Function, and Beyond
Bialik, S., & Kimchi, A. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142615 · Cited by 440
Kirchheiner, J., Schmidt, H., Tzvetkov, M., Keulen, J.-T., Lötsch, J., Roots, I., & Brockmöller, J. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500406 · Cited by 439
Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium
Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212635200 · Cited by 435
Alzheimer’s disease pathogenesis and therapeutic interventions
Parihar, M. S., & Hemnani, T. (2004) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.12.007 · Cited by 433
The complexity of mitogen-activated protein kinases (MAPKs) made simple
Krishna, M., & Narang, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8170-7 · Cited by 432
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Clayburgh, D. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24970 · Cited by 426
O'Brien, W. T., Harper, A. D., Jové, F., Woodgett, J. R., Maretto, S., Piccolo, S., & Klein, P. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4753-03.2004 · Cited by 415
Glycogen synthase kinase 3: A key regulator of cellular fate
Forde, J. E., & Dale, T. C. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7045-7 · Cited by 385
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R., & Roh, M.-S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382
p38 Kinase Is Activated in the Alzheimer's Disease Brain
Hensley, K., Floyd, R. A., Zheng, N., Nael, R., Robinson, K. A., Nguyen, X., Pye, Q. N., Stewart, C. A., Geddes, J., Markesbery, W. R., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722053.x · Cited by 373
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Applications for ROCK kinase inhibition
Olson, M. F. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.002 · Cited by 347
Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke
McCullough, L. D., Zeng, Z., Li, H., Landree, L. E., McFadden, J., & Ronnett, G. V. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409985200 · Cited by 333
Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons
Muñoz-Montaño, J. R., Moreno, F. J., Avila, J., & Dı́az-Nido, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00688-1 · Cited by 322
Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho
Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., Gonzalez-DeWhitt, P. A., Gelfanova, V., Hale, J. E., May, P. C., et al. (2003) · Science · doi:10.1126/science.1090154 · Cited by 316
Gould, T. D., Einat, H., Bhat, R., & Manji, H. K. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004535 · Cited by 314
Pirvola, U., Xing-Qun, L., Virkkala, J., Saarma, M., Murakata, C., Camoratto, A. M., Walton, K. M., & Ylikoski, J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00043.2000 · Cited by 307
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292
Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Kockeritz, L., Doble, B., Patel, S., & Woodgett, J. (2006) · Current Drug Targets · doi:10.2174/1389450110607011377 · Cited by 284
Ebselen: prospective therapy for cerebral ischaemia
Parnham, M., & Sies, H. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.607 · Cited by 283
Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux
Dai, H., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 273
Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System
Inglis, K. J., Chereau, D., Brigham, E. F., Chiou, S.-S., Schöbel, S., Frigon, N. L., Yu, M., Caccavello, R. J., Nelson, S., Motter, R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.c800206200 · Cited by 240
p38 Pathway Kinases as Anti-inflammatory Drug Targets
Schindler, J. F., Monahan, J. B., & Smith, W. G. (2007) · Journal of Dental Research · doi:10.1177/154405910708600902 · Cited by 227
Raymond, E., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P. M. J., Frenay, M., Rampling, R., Stupp, R., Kros, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9235 · Cited by 227
Munoz, L., Ranaivo, H. R., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Chico, L. W., Van Eldik, L. J., & Watterson, D. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-21 · Cited by 224
Self-citationLiu, S. J., Zhang, A. H., Li, H. L., Wang, Q., Deng, H. M., Netzer, W. J., Xu, H., & Wang, J. Z. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02070.x · Cited by 223
Bidirectional signals transduced by DAPK–ERK interaction promote the apoptotic effect of DAPK
Chen, C., Wang, W., Kuo, J., Tsai, H., Lin, J., Chang, Z., & Chen, R. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600510 · Cited by 220
P38 MAP kinase is activated at early stages in Alzheimer's disease brain
Sun, A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00180-8 · Cited by 219
Barone, F. C., Irving, E. A., Ray, A. M., Lee, J. C., Kassis, S., Kumar, S., Badger, A. M., White, R. F., McVey, M. J., Legos, J. J., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38747-6 · Cited by 214
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
Zarate, C. A., Singh, J. B., Carlson, P. J., Quiroz, J., Jolkovsky, L., Luckenbaugh, D. A., & Manji, H. K. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00530.x · Cited by 208
Ferrer, I., Blanco, R., Carmona, M., & Puig, B. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100016 · Cited by 207
MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Wang, L. H., & Johnson, E. M. (2008) · Neurology · doi:10.1212/01.wnl.0000324506.93877.5e · Cited by 204
From fragment to clinical candidate—a historical perspective
Chessari, G., & Woodhead, A. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.04.007 · Cited by 202
Schizophrenia as a GSK-3 dysregulation disorder
Lovestone, S., Killick, R., Di Forti, M., & Murray, R. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.02.002 · Cited by 192
Kamath, A. V., Wang, J., Lee, F. Y., & Marathe, P. H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0478-8 · Cited by 191
Giovannini, M. G., Scali, C., Prosperi, C., Bellucci, A., Vannucchi, M. G., Rosi, S., Pepeu, G., & Casamenti, F. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0538 · Cited by 190
Lloyd, E., Somera-Molina, K., Van Eldik, L. J., Watterson, D. M., & Wainwright, M. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-28 · Cited by 180
Self-citationDevelopment of specific Rho-kinase inhibitors and their clinical application
Tamura, M., Nakao, H., Yoshizaki, H., Shiratsuchi, M., Shigyo, H., Yamada, H., Ozawa, T., Totsuka, J., & Hidaka, H. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.06.015 · Cited by 178
Transforming fragments into candidates: small becomes big in medicinal chemistry
de Kloe, G. E., Bailey, D., Leurs, R., & de Esch, I. J. P. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.03.009 · Cited by 178
Sheng, J. G., Jones, R. A., Zhou, X. Q., McGinness, J. M., Van Eldik, L. J., Mrak, R. E., & Griffin, W. S. T. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00041-9 · Cited by 176
Self-citationAtzori, C., Ghetti, B., Piva, R., Srinivasan, A. N., Zolo, P., Delisle, M. B., Mirra, S. S., & Migheli, A. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.12.1190 · Cited by 175
Ferrer, I., Blanco, R., Carmona, M., Puig, B., Barrachina, M., Gómez, C., & Ambrosio, S. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100015 · Cited by 172
Mitogen-Activated Protein Kinase Inhibition in Traumatic Brain Injury: In Vitro and In Vivo Effects
Mori, T., Wang, X., Jung, J.-C., Sumii, T., Singhal, A. B., Fini, M. E., Dixon, C. E., Alessandrini, A., & Lo, E. H. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200204000-00008 · Cited by 168
A feasibility and tolerability study of lithium in Alzheimer's disease
Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 163
p38 MAP kinase inhibitors: many are made, but few are chosen.
Dominguez, C., Powers, D. A., & Tamayo, N. A. (2005) · PubMed · Cited by 163
Satoh, S.-I., Utsunomiya, T., Tsurui, K., Kobayashi, T., Ikegaki, I., Sasaki, Y., & Asano, T. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01229-2 · Cited by 161
Wang, W., Shi, L., Xie, Y., Ma, C., Li, W., Su, X., Huang, S., Chen, R., Zhu, Z., Mao, Z., et al. (2004) · Neuroscience Research · doi:10.1016/j.neures.2003.10.012 · Cited by 160
Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain
. Swatton, J. E., Sellers, L. A., Faull, R. L. M., Holland, A., Iritani, S., & Bahn, S. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03365.x · Cited by 159
Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity
Wang, W., Yang, Y., Ying, C., Li, W., Ruan, H., Zhu, X., You, Y., Han, Y., Chen, R., Wang, Y., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.03.017 · Cited by 158
Mixed-Lineage Kinases: A Target for the Prevention of Neurodegeneration
Wang, L. H., Besirli, C. G., & Johnson, E. M. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121840 · Cited by 145
Wainwright, M. S., Rossi, J. L., Schavocky, J. P., Crawford, S. E., Steinhorn, D. M., Velentza, A. V., Zasadzki, M., Shirinsky, V. P., Jia, Y., Haiech, J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031595100 · Cited by 141
Self-citationWang, Z.-Q., Wu, D., Huang, F., & Yang, G. (2003) · Brain Research · doi:10.1016/j.brainres.2003.09.074 · Cited by 138
Selenica, M. L., Jensen, H. S., Larsen, A. K., Pedersen, M. L., Helboe, L., Leist, M., & Lotharius, J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707471 · Cited by 138
Nath, N., Giri, S., Prasad, R. C., Salem, M. L., Singh, A. K., & Singh, I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.1.566 · Cited by 136
Karunakaran, S., Saeed, U., Mishra, M., Valli, R. K., Joshi, S. D., Meka, D. P., Seth, P., & Ravindranath, V. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4511-08.2008 · Cited by 134
Role of c‐Jun N‐terminal kinase in early brain injury after subarachnoid hemorrhage
Yatsushige, H., Ostrowski, R. P., Tsubokawa, T., Colohan, A. R. T., & Zhang, J. H. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21281 · Cited by 134
Dewil, M., dela Cruz, V. F., Van Den Bosch, L., & Robberecht, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.023 · Cited by 133
Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice
Rosa, A. O., Kaster, M. P., Binfaré, R. W., Morales, S., Martín-Aparicio, E., Navarro-Rico, M. L., Martínez, A., Medina, M., García, A. G., López, M. G., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.020 · Cited by 132
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease
Hye, A., Kerr, F., Archer, N. J., Foy, C., Poppe, M., Brown, R. G., Hamilton, G., Powell, J. F., Anderton, B. H., & Lovestone, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.031 · Cited by 131
DAPK1 variants are associated with Alzheimer's disease and allele-specific expression
Li, Y., Grupe, A., Rowland, C. M., Nowotny, P., Kauwe, J. S. K., Smemo, S., Hinrichs, A. L., Tacey, K. M., Toombs, T. A., Kwok, S., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl178 · Cited by 130
Targeting JNK3 for the treatment of neurodegenerative disorders
Resnick, L., & Fennell, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03251-9 · Cited by 129
Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease
Gandhi, P. N., Chen, S. G., & Wilson‐Delfosse, A. L. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21949 · Cited by 127
GSK-3 Inhibitors: A Ray of Hope for the Treatment of Alzheimer's Disease?
Martínez, A., & Pérez, D. I. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15204 · Cited by 125
The therapeutic effects of Rho-ROCK inhibitors on CNS disorders
Kubo, T., Yamaguchi, A., Iwata, N., & Yamashita, T. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s2907 · Cited by 123
Morphy, R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0512185 · Cited by 123
Piao, C. S., Kim, J., Han, P., & Lee, J. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10671 · Cited by 122
Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity
Arendt, R., Greenblatt, D. J., Liebisch, D., Luu, M., & Paul, S. M. (1987) · Psychopharmacology · doi:10.1007/bf02439589 · Cited by 120
Węgiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur‐Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, ., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0419-6 · Cited by 119
Death-associated Protein Kinase Is Activated by Dephosphorylation in Response to Cerebral Ischemia
Shamloo, M., Soriano, L., Wieloch, T. W., Nikolich, K., Urfer, R., & Oksenberg, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505804200 · Cited by 117
Luna‐Medina, R., Cortés‐Canteli, M., Sánchez-Galiano, S., Morales-Garcia, J. A., Martínez, A., Santos, Á., & Pérez‐Castillo, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1004-07.2007 · Cited by 116
Demuth, T., Reavie, L. B., Rennert, J. L., Nakada, M., Nakada, S., Hoelzinger, D. B., Beaudry, C. E., Henrichs, A. N., Anderson, E., & Berens, M. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0711 · Cited by 115
Shani, G., Marash, L., Gözüaçık, D., Bialik, S., Teitelbaum, L., Shohat-Ophir, G., & Kimchi, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8611-8626.2004 · Cited by 115
Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment
Cohen, Y., Chetrit, A., Cohen, Y., Sirota, P., & Modan, B. (1998) · Medical Oncology · doi:10.1007/bf02787342 · Cited by 109
Identification of MEK1 as a novel target for the treatment of neuropathic pain
Ciruela, A., Dixon, A. K., Bramwell, S., González, M. I., Pinnock, R. D., & Lee, K. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705103 · Cited by 109
Roscovitine Reduces Neuronal Loss, Glial Activation, and Neurologic Deficits after Brain Trauma
Hilton, G. D., Stoica, B. A., Byrnes, K. R., & Faden, A. I. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.75 · Cited by 108
Kozikowski, A. P., Gaisina, I. N., Petukhov, P. A., Sridhar, J., King, L. T., Blond, S. Y., Duka, T., Rusnak, M., & Sidhu, A. (2006) · ChemMedChem · doi:10.1002/cmdc.200500039 · Cited by 107
Shapira, M., Licht-Murava, A., Milman, A., Pick, C. G., Shohami, E., & Eldar-Finkelman, H. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.12.006 · Cited by 106
Zhang, D., Kanthasamy, A., Yang, Y., Anantharam, V., & Kanthasamy, A. G. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4107-06.2007 · Cited by 104
DAP kinase regulates JNK signaling by binding and activating protein kinase D under oxidative stress
Eisenberg‐Lerner, A., & Kimchi, A. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402212 · Cited by 104
SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
Legos, J. J., Erhardt, J. A., White, R. F., Lenhard, S. C., Chandra, S., Parsons, A. A., Tuma, R. F., & Barone, F. C. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03228-5 · Cited by 100
Weishaupt, J. H. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00221-5 · Cited by 100
Wang, F., Corbett, D., Osuga, H., Osuga, S., Ikeda, J., Slack, R. S., Hogan, M. J., Hakim, A. M., & Park, D. S. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200202000-00005 · Cited by 99
Saporito, M. S., Hudkins, R. L., & Maroney, A. C. (2002) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70081-x · Cited by 98
Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs
Martínez, A. (2008) · Medicinal Research Reviews · doi:10.1002/med.20119 · Cited by 98
Kelly, S., Zhao, H., Sun, G. H., Cheng, D., Qiao, Y., Luo, J., Martin, K., Steinberg, G. K., Harrison, S. D., & Yenari, M. A. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.04.004 · Cited by 96
Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model
Tran, T.-T., Uhl, M., Jing, Y., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-010 · Cited by 96
Waldmeier, P. C., Bozyczko‐Coyne, D., Williams, M. J., & Vaught, J. L. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.031 · Cited by 95
Aminopyridazines inhibit β-amyloid-induced glial activation and neuronal damage in vivo
Craft, J. M., Watterson, D. M., Frautschy, S. A., & Eldik, L. J. V. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.01.006 · Cited by 94
Self-citationPotential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Dambach, D. M. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054985911 · Cited by 93
Tian, J.-H., Das, S., & Sheng, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300492200 · Cited by 93
Bialik, S., Bresnick, A. R., & Kimchi, A. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401386 · Cited by 93
Velentza, A. V., Wainwright, M. S., Zasadzki, M., Mirzoeva, S., Schumacher, A. M., Haiech, J., Focia, P. J., Egli, M., & Watterson, D. M. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00733-9 · Cited by 93
Self-citationKozikowski, A. P., Gaisina, I. N., Yuan, H., Petukhov, P. A., Blond, S. Y., Fedolak, A., Caldarone, B. J., & McGonigle, P. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068969w · Cited by 89
CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice
Apostol, B. L., Simmons, D. A., Zuccato, C., Illes, K., Pallos, J., Casale, M., Conforti, P., Ramos, C., Roarke, M., Kathuria, S., et al. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.04.007 · Cited by 88
Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
Medina, M., & Castro, A. C. G. (2008) · PubMed · Cited by 83
Obradovic, T., Dobson, G. G., Shingaki, T., Kungu, T., & Hidalgo, I. J. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9149-4 · Cited by 83
Koh, S., Kim, Y., Kim, H. Y., Hwang, S., Lee, C. H., & Kim, S. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.03.004 · Cited by 83
Chemical Genetics Define the Roles of p38α and p38β in Acute and Chronic Inflammation
O’Keefe, S. J., Mudgett, J. S., Cupo, S. H., Parsons, J. N., Chartrain, N. A., Fitzgerald, C. E., Chen, S.-L., Lowitz, K., Rasa, C. G., Visco, D. M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704236200 · Cited by 81
Sun, X., Minohara, M., Kikuchi, H., Ishizu, T., Tanaka, M., Piao, H. Z., Osoegawa, M., Ohyagi, Y., Shimokawa, H., & Kira, J. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.027 · Cited by 80
Glycogen synthase kinase‐3β and tau genes interact in Alzheimer's disease
Kwok, J. B., Loy, C. T., Hamilton, G., Lau, E., Hallupp, M., Williams, J. H., Owen, M. J., Broe, G. A., Tang, N. L. S., LAM, L. C. W., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21476 · Cited by 77
Targeting the gatekeeper residue in phosphoinositide 3-kinases
Alaimo, P. J., Knight, Z. A., & Shokat, K. M. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.02.021 · Cited by 77
VX-745. Vertex Pharmaceuticals.
Haddad, J. J. (2001) · PubMed · Cited by 77
Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Huang, H., & Klein, P. S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011389 · Cited by 76
Ito, T., Ohtori, S., Inoue, G., Koshi, T., Doya, H., Ozawa, T., Saito, T., Moriya, H., & Takahashi, K. (2007) · Spine · doi:10.1097/01.brs.0000251437.10545.e9 · Cited by 68
Wrobleski, S. T., & Doweyko, A. M. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026054985894 · Cited by 67
Glycogen Synthase Kinase-3β Inhibition Reduces Secondary Damage in Experimental Spinal Cord Trauma
Cuzzocrea, S., Genovese, T., Mazzon, E., Crisafulli, C., Paola, R. D., Muià, C., Collin, M., Esposito, E., Bramanti, P., & Thiemermann, C. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102863 · Cited by 66
da Cunha, J. M., Rae, G. A., Ferreira, S. H., & Cunha, F. Q. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.004 · Cited by 64
Breslin, J. W., Sun, H., Xu, W., Rodarte, C., Moy, A. B., Wu, M. H., & Yuan, S. Y. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00238.2005 · Cited by 64
Antiepileptic effects of two Rho‐kinase inhibitors, Y‐27632 and fasudil, in mice
İnan, S. Y., & Büyükafşar, K. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.225 · Cited by 61
Discovery of Highly Selective and Potent p38 Inhibitors Based on a Phthalazine Scaffold
Herberich, B., Cao, G., Chakrabarti, P. P., Falsey, J. R., Pettus, L. H., Rzasa, R. M., Reed, A. B., Reichelt, A. F., Sham, K. K. C., Thaman, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8005417 · Cited by 60
Thotala, D. K., Hallahan, D. E., & Yazlovitskaya, E. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6327 · Cited by 60
Bogatcheva, N. V., Adyshev, D. M., Mambetsariev, B., Moldobaeva, N., & Verin, A. D. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00217.2006 · Cited by 60
Gould, T. D. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00096-3 · Cited by 59
The role of membrane transporters in drug delivery to brain tumors
Nies, A. T. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.023 · Cited by 59
Glicksman, M. A., Chiu, A. Y., Dionne, C. A., Harty, M. W., Kaneko, M., Murakata, C., Oppenheim, R. W., Prevette, D. M., Sengelaub, D. R., Vaught, J. L., et al. (1998) · Journal of Neurobiology · Cited by 57
Nikolić, M. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8032-1 · Cited by 56
Strategies for the Design of Potent and Selective Kinase Inhibitors
McInnes, C., & Fischer, P. M. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764850 · Cited by 54
JNK inhibition as a potential strategy in treating Parkinson's disease
Wang, W., Ma, C.-L., Mao, Z., & Li, M. (2004) · Drug News & Perspectives · doi:10.1358/dnp.2004.17.10.873916 · Cited by 52
Reynoso, R., Perrin, R. M., Breslin, J. W., Daines, D. A., Watson, K. D., Watterson, D. M., Wu, M. H., & Yuan, S. Y. (2007) · Shock · doi:10.1097/shk.0b013e31804d415f · Cited by 51
Self-citationConforti, P., Ramos, C., Apostol, B. L., Simmons, D. A., Nguyen, H. P., Rieß, O., Thompson, L. M., Zuccato, C., & Cattaneo, E. F. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.04.012 · Cited by 49
Carboni, S., Boschert, U., Gaillard, P., Gotteland, J., Gillon, J., & Vitte, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707574 · Cited by 49
Schumacher, A. M., Velentza, A. V., Watterson, D. M., & Wainwright, M. S. (2002) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/s1570-9639(02)00453-3 · Cited by 49
Self-citationJadhav, V. R., Matchett, G. A., Hsu, F. P. K., & Zhang, J. H. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.4.680 · Cited by 48
Hudkins, R. L., Diebold, J. L., Tao, M., Josef, K. A., Park, C. H., Angeles, T. S., Aimone, L. D., Husten, J., Ator, M. A., Meyer, S. L., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8005838 · Cited by 47
Schumacher, A. M., Schavocky, J. P., Velentza, A. V., Mirzoeva, S., & Watterson, D. M. (2004) · Biochemistry · doi:10.1021/bi049589v · Cited by 46
Self-citationThe p38α mitogen-activated protein kinase as a central nervous system drug discovery target
Borders, A. S., de Almeida, L., Eldik, L. J. V., & Watterson, D. M. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s12 · Cited by 45
Self-citationTrieu, V. N., Liu, R., Liu, X., & Uckun, F. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1905 · Cited by 44
Rossi, J. L., Velentza, A. V., Steinhorn, D. M., Watterson, D. M., & Wainwright, M. S. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00380.2006 · Cited by 44
Self-citationGlycogen Synthase Kinase 3 Beta (GSK-3β) as a Therapeutic Target in NeuroAIDS
Dewhurst, S., Maggirwar, S. B., Schifitto, G., Gendelman, H. E., & Gelbard, H. A. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9051-1 · Cited by 42
Rishton, G. M., LaBonte, K., Williams, A. J., Kassam, K., & Kolovanov, E. A. (2006) · PubMed · Cited by 40
Saporito, M. S., Brown, E. R., Carswell, S., DiCamillo, A., Miller, M. S., Murakata, C., Neff, N. T., Vaught, J. L., & Haun, F. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00059-1 · Cited by 40
Ranaivo, H. R., Carusio, N., Wangensteen, R., Ohlmann, P., Loichot, C., Tesse, A., Chalupský, K., Lobysheva, I. I., Haiech, J., Watterson, D. M., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060219 · Cited by 40
Self-citationInhibition of Aβ production and APP maturation by a specific PKA inhibitor
Yuan, S., Ryder, J. W., & Ni, B. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00645-8 · Cited by 40
Inhibitors of cAMP-Dependent Protein Kinase Impair Long-Term Memory Formation in Day-Old Chicks
Zhao, W., Polya, G. M., Wang, B. H., Gibbs, M. E., Sedman, G. L., & Ng, K. (1995) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1995.1049 · Cited by 39
Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions
Koh, S., Yoo, A., Chang, D., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.006 · Cited by 38
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons
Liu, D., Cheng, X., Ander, B. P., Xu, H., Davis, R. R., Gregg, J. P., & Sharp, F. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.01.006 · Cited by 38
Satoh, S.-I., Toshima, Y., Ikegaki, I., Iwasaki, M., & Asano, T. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.027 · Cited by 36
Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice
Büyükafşar, K., Yalçın, İ., Kurt, A. H., Tiftik, R. N., Şahan-Fırat, S., & Aksu, F. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.042 · Cited by 36
Schumacher, A. M., Velentza, A. V., Watterson, D. M., & Dresios, J. (2006) · Biochemistry · doi:10.1021/bi060413y · Cited by 32
Self-citationKinases as drug targets in the treatment of bipolar disorder
Catapano, L. A., & Manji, H. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.007 · Cited by 29
Death associated protein kinase as a potential therapeutic target
Schumacher, A. M., Velentza, A. V., & Watterson, D. M. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.4.497 · Cited by 28
Self-citationThe identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase
Takle, A. K., Bamford, M. J., Davies, S., Davis, R. P., Dean, D. K., Gaiba, A., Irving, E. A., King, F. D., Naylor, A., Parr, C. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.070 · Cited by 26
Enzyme Kinetics and Binding Studies on Inhibitors of MEK Protein Kinase
VanScyoc, W. S., Holdgate, G. A., Sullivan, J. E., & Ward, W. H. J. (2008) · Biochemistry · doi:10.1021/bi701811x · Cited by 26
Stirling, D. P., Liu, J., Plunet, W., Steeves, J. D., & Tetzlaff, W. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.007 · Cited by 22
Cowper-Smith, C. D., Anger, G. J., Magal, E., Norman, M. H., & Robertson, G. S. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.051 · Cited by 21
Chico, L. K., Behanna, H. A., Hu, W., Zhong, G., Roy, S. M., & Watterson, D. M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028134 · Cited by 20
Self-citationMEK‐inhibitor U0126 in hyperglycaemic focal ischaemic brain injury in the rat
Farrokhnia, N., Ericsson, A. B., Terént, A., & Lennmyr, F. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.01990.x · Cited by 18
Tokuyama, S., Ho, I. K., & Yamamoto, T. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00273-2 · Cited by 16
Behanna, H. A., Watterson, D. M., & Ranaivo, H. R. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.08.007 · Cited by 14
Self-citationCarr, K. D., de Vaca, S. C., Sun, Y., Chau, L. S., Pan, Y., & Cruz, J. D. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1313-6 · Cited by 13
Inhibition of abeta production and APP maturation by specific PKA inhibitors
Su, Y., Ryder, J. W., Li, D., Bender, M., Ivengar, S., Hyslop, P. A., & Ni, B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83397-7 · Cited by 10
Cited by
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Axonal transport and neurological disease
Sleigh, J. N., Rossor, A. M., Fellows, A. D., Tosolini, A. P., & Schiavo, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0257-2 · Cited by 316
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
Metadata
- Authors
- Chico, L. K., Van Eldik, L. J., & Watterson, D. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-11
- Volume
- 8
- Issue
- 11
- Pages
- 892-909
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1964892539
- Cited by
- 298
- References
- 187
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.